Cholecystokinin expression in the β-cell leads to increased β-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 309, Issue 10, 2015, Pages 819-828

  Lavine, Jeremy A ^a   Kibbe, Carly R ^a   Baan, Mieke ^a   Sirinvaravong, Sirinart ^a   Umhoefer, Heidi M ^a   Engler, Kimberly A ^a   Meske, Louise M ^a   Sacotte, Kaitlyn A ^a   Erhardt, Daniel P ^a   Davis, Dawn Belt ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Aging; Apoptosis; Cholecystokinin; Islet; Streptozotocin; cell

Indexed keywords

CHOLECYSTOKININ; HUMAN GROWTH HORMONE; CYTOKINE; INS1 PROTEIN, MOUSE; INSULIN; RECOMBINANT PROTEIN; STREPTOZOCIN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; BODY WEIGHT; CELL EXPANSION; CELL PROTECTION; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; OBESITY; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSGENE; TRANSGENIC MOUSE; AGING; ANIMAL; BLOOD; CELL LINE; CYTOLOGY; DIABETES MELLITUS, TYPE 2; DOWN REGULATION; GENETICS; HYPERGLYCEMIA; MALE; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY; PHYSIOLOGICAL STRESS; RAT; SECRETION (PROCESS); TISSUE CULTURE TECHNIQUE;

AGING; ANIMALS; APOPTOSIS; CELL LINE; CHOLECYSTOKININ; CYTOKINES; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; RATS; RECOMBINANT PROTEINS; STREPTOZOCIN; STRESS, PHYSIOLOGICAL; TISSUE CULTURE TECHNIQUES;

EID: 84947294686     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00159.2015     Document Type: Article

References (52)

1. Ahren B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85: 1043-1048, 2000.
2. Ahren B, Pettersson M, Uvnäs-Moberg K, Gutniak M, Efendic S. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res Clin Pract 13: 153-161, 1991.
3. Baan M, Kibbe CR, Bushkofsky JR, Harris TW, Sherman DS, Davis DB. Transgenic expression of the human growth hormone minigene promotes pancreatic beta cell proliferation. Am J Physiol Regul Integr Comp Physiol. 2015 Jul 22:ajpregu.00244.2015. doi: 10.1152/ajpregu.00244.2015
4. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgard CB. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43: 161-189, 1994.
5. Bourassa J, Lainé J, Kruse ML, Gagnon MC, Calvo É, Morisset J. Ontogeny and species differences in the pancreatic expression and localization of the CCK(A) receptors. Biochem Biophys Res Commun 260: 820-828, 1999.
6. Brouwers B, de Faudeur G, Osipovich AB, Goyvaerts L, Lemaire K, Boesmans L, Cauwelier EJG, Granvik M, Pruniau VPEG, Van Lommel L, Van Schoors J, Stancill JS, Smolders I, Goffin V, Binart N, In’t Veld P, Declercq J, Magnuson MA, Creemers JWM, Schuit F, Schraenen A. Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab 20: 979-990, 2014.
7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
8. Centers for Disease Control, and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014.
9. Chen S, Turner S, Tsang E, Stark J, Turner H, Mahsut A, Keifer K, Goldfinger M, Hellerstein MK. Measurement of pancreatic islet cell proliferation by heavy water labeling. Am J Physiol Endocrinol Metab 293: E1459-E1464, 2007.
10. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62: 3316-3323, 2013.
11. Dufresne M. Cholecystokinin and Gastrin Receptors. Physiol Rev 86: 805-847, 2006.
12. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AMK, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489, 2011.
13. Fridolf T, Karlsson S, Ahren B. Role of extracellular Na + on CCK-8-induced insulin secretion. Biochem Biophys Res Commun 192: 1162-1168, 1993.
14. Gu Z, Du Y, Liu Y, Ma L, Li L, Gong Y, Tian H, Li C. Effect of aging on islet beta-cell function and its mechanisms in Wistar rats. Age (Dordr) 34: 1393-1403, 2012.
15. Guenifi A, Ahren B, Abdel-Halim SM. Differential effects of glucagonlike peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. Pancreas 22: 58-64, 2001.
16. Hanley SC, Austin E, Assouline-Thomas B, Kapeluto J, Blaichman J, Moosavi M, Petropavlovskaia M, Rosenberg L. β-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 151: 1462-1472, 2010.
17. Hansen AMK, Bödvarsdottir TB, Nordestgaard DNE, Heller RS, Gotfredsen CF, Maedler K, Fels JJ, Holst JJ, Karlsen AE. Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus- an adaptive response to hyperglycaemia? Diabetologia 54: 1379-1387, 2011.
18. Hara M, Wang X, Kawamura T, Bindokas VP, Dizon RF, Alcoser SY, Magnuson MA, Bell GI. Transgenic mice with green fluorescent proteinlabeled pancreatic β-cells. Am J Physiol Endocrinol Metab 284: E177-E183, 2003.
19. Irwin N, Frizelle P, Montgomery IA, Moffett RC, O’Harte FPM, Flatt PR. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia 55: 2747-2758, 2012.
20. Irwin N, Frizelle P, O’Harte FPM, Flatt PR. Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice. J Endocrinol 216: 53-59, 2013.
21. Irwin N, Montgomery IA, Moffett RC, Flatt PR. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Biochem Pharmacol 85: 81-91, 2013.
22. Irwin N, Pathak V, Flatt PR. A Novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice. Diabetes 64: 2996-3009, 2015.
23. Kageyama H, Kita T, Horie S, Takenoya F, Funahashi H, Kato S, Hirayama M, Young Lee E, Sakurai J, Inoue S, Shioda S. Immunohistochemical analysis of cholecystokinin A receptor distribution in the rat pancreas. Regul Pept 126: 137-143, 2005.
24. Karlsson S, Ahren B. CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors. Eur J Pharmacol 213: 145-146, 1992.
25. Karlsson S, Sundler F, Ahren B. CCK receptor subtype in insulinproducing cells: a combined functional and in situ hybridization study in rat islets and a rat insulinoma cell line. Regul Pept 78: 95-103, 1998.
26. Keller MP, Choi Y, Wang P, Davis DB, Rabaglia ME, Oler AT, Stapleton DS, Argmann C, Schueler KL, Edwards S, Steinberg HA, Chaibub Neto E, Kleinhanz R, Turner S, Hellerstein MK, Schadt EE, Yandell BS, Kendziorski C, Attie AD. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 18: 706-716, 2008.
27. Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic β-cells in mouse models of ß-cell regeneration. Islets 2: 149-155, 2010.
28. Konno K, Takahashi-Iwanaga H, Uchigashima M, Miyasaka K, Funakoshi A, Watanabe M, Iwanaga T. Cellular and subcellular localization of cholecystokinin (CCK)-1 receptors in the pancreas, gallbladder, and stomach of mice. Histochem Cell Biol 143: 301-312, 2015.
29. Kuntz E, Pinget M, Damgé P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP 5: 464-475, 2004.
30. Kushner JA. The role of aging upon β cell turnover. J Clin Invest 123: 990-995, 2013.
31. Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of β-cell mass. Ann NY Acad Sci 1212: 41-58, 2010.
32. Lavine JA, Raess PW, Davis DB, Rabaglia ME, Presley BK, Keller MP, Beinfeld MC, Kopin AS, Newgard CB, Attie AD. Contamination with E1A-positive wild-type adenovirus accounts for species-specific stimulation of islet cell proliferation by CCK: a cautionary note. Mol Endocrinol 24: 464-467, 2010.
33. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL, Koltes JE, Dawson JA, Yandell BS, Samuelson LC, Beinfeld MC, Davis DB, Hellerstein MK, Keller MP, Attie AD. Cholecystokinin is up-regulated in obese mouse islets and expands betacell mass by increasing beta-cell survival. Endocrinology 151: 3577-3588, 2010.
34. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL, Koltes JE, Dawson JA, Yandell BS, Samuelson LC, Beinfeld MC, Davis DB, Hellerstein MK, Keller MP, Attie AD. Cholecystokinin is up-regulated in obese mouse islets and expands betacell mass by increasing beta-cell survival. Endocrinology 151: 3577-3588, 2010.
35. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003.
36. Lilla V, Webb G, Rickenbach K, Maturana A, Steiner DF, Halban PA, Irminger JC. Differential gene expression in well-regulated and dysregulated pancreatic beta-cell (MIN6) sublines. Endocrinology 144: 1368-1379, 2003.
37. Linnemann AK, Neuman JC, Battiola TJ, Wisinski JA, Kimple ME, Davis DB. Glucagon-like peptide-1 regulates cholecystokinin production in β-cells to protect from apoptosis. Mol Endocrinol 29: 978-987, 2015.
38. Lo CM, Obici S, Dong HH, Haas M, Lou D, Kim DH, Liu M, D’Alessio D, Woods SC, Tso P. Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60: 2000-2007, 2011.
39. Maedler K, Schumann DM, Schulthess F, Oberholzer J, Bosco D, Berney T, Donath MY. Aging correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. Diabetes 55: 2455-2462, 2006.
40. Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagonlike peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137: 2146-2157, 2009.
41. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D’Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55: 3262-3272, 2012.
42. Mellado-Gil J, Rosa TC, Demirci C, Gonzalez-Pertusa JA, Velazquez-Garcia S, Ernst S, Valle S, Vasavada RC, Stewart AF, Alonso LC, Garcia-Ocana A. Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes. Diabetes 60: 525-536, 2011.
43. Morisset J, Julien S, Lainé J. Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem 51: 1501-1513, 2003.
44. Ning SL, Zheng WS, Su J, Liang N, Li H, Zhang D, Dong JH, Zhang ZK, Cui M, Hu QX, Chen CC, Liu CH, Wang C, Pang Q, Chen Y, Yu X, Sun JP. Different downstream signaling of CCKAR regulates distinct functions of CCK in pancreatic β cells. Br J Pharmacol. 2015 Aug 6. doi:10.1111/bph.13271
45. Oropeza D, Jouvet N, Budry L, Campbell JE, Bouyakdan K, Lacombe J, Perron G, Bergeron V, Neuman JC, Brar HK, Fenske RJ, Meunier C, Sczelecki S, Kimple ME, Drucker DJ, Screaton RA, Poitout V, Ferron M, Alquier T, Estall JL. Phenotypic characterization of MIPCreERT1Lphi mice with transgene-driven islet expression of human growth hormone. Diabetes. 2015 Jul 7. pii: db150272
46. Rabaglia ME, Gray-Keller MP, Frey BL, Shortreed MR, Smith LM, Attie AD. α-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice. Am J Physiol Endocrinol Metab 289: E218-E224, 2005.
47. Rodgers RJ, Tschop MH, Wilding JPH. Anti-obesity drugs: past, present and future. Disease Models & Mechanisms 5: 621-626, 2012.
48. Schweiger M, Erhard MH, Amselgruber WM. Cell-specific localization of the cholecystokininA receptor in the porcine pancreas. Anat Histol Embryol 29: 357-361, 2000.
49. Teta M, Long SY, Wartschow LM, Rankin MM, kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes 54: 2557-2567, 2005.
50. Truchan NA, Brar HK, Gallagher SJ, Neuman JC, Kimple ME. Validation of a single-islet microplate assay to measure mouse and human islet insulin secretion. Islets. In press, 2015. doi: 10.1080/19382014.2015.1076607.
51. Tschen SI, Dhawan S, Gurlo T, Bhushan A. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 58: 1312-1320, 2009.
52. Willemer S, Elsasser HP, Adler G. Hormone-induced pancreatitis. Eur Surg Res 24, Suppl 1: 29-39, 1992.